Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting: Our Bureau, Bengaluru Friday, January 9, 2026, 12:15 Hrs [IST] Shilp ...

A research team led by Hiroshima University and Tokyo University of Agriculture and Technology have proposed a neuroendocrine ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Spoiler alert! The following contains details from Season 5, Episode 3 of "Stranger Things," "The Turnbow Trap." These kids are up to their old tricks. We're talking barbed wire, demogorgons on fire, ...

Chemotherapy-induced nausea and vomiting (CINV) represents one of the most distressing and debilitating side effects experienced by cancer patients undergoing treatment, significantly impacting ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...

Background Insulin-like peptide 5 (INSL5) is an enteroendocrine hormone expressed in distal colonic ‘L cells’. Bile acid receptor agonists are known to stimulate INSL5 secretion in primary cell ...

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – ...

In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who had received one previous line ...